Advances in Nanoplatforms for Immunotherapy Applications Targeting the Tumor Microenvironment
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.3c00846 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Nannan Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Medicine Center, Clinical Research Institute, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical Colleg…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 129 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Department of Education of Zhejiang Province, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Cancer immunotherapy is a treatment method that activates or enhances the autoimmune response of the body to fight tumor growth and metastasis, has fewer toxic side effects and a longer-lasting efficacy than radiotherapy and chemotherapy, and has become an important means for the clinical treatment of cancer. However, clinical results from immunotherapy have shown that most patients lack responsiveness to immunotherapy and cannot benefit from this treatment strategy. The tumor microenvironment (TME) plays a critical role in the response to immunotherapy. The TME typically prevents effective lymphocyte activation, reducing their infiltration, and inhibiting the infiltration of effector T cells. According to the characteristic differences between the TME and normal tissues, various nanoplatforms with TME targeting and regulation properties have been developed for more precise regulation of the TME and have the ability to codeliver a variety of active pharmaceutical ingredients, thereby reducing systemic toxicity and improving the therapeutic effect of antitumor. In addition, the precise structural design of the nanoplatform can integrate specific functional motifs, such as surface-targeted ligands, degradable backbones, and TME stimulus-responsive components, into nanomedicines, thereby reshaping the tumor microenvironment, improving the body's immunosuppressive state, and enhancing the permeability of drugs in tumor tissues, in order to achieve controlled and stimulus-triggered release of load cargo. In this review, the physiological characteristics of the TME and the latest research regarding the application of TME-regulated nanoplatforms in improving antitumor immunotherapy will be described. Furthermore, the existing problems and further applications perspectives of TME-regulated platforms for cancer immunotherapy will also be discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory Medicine Center, Clinical Research Institute, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310014, China.
- Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang 310006, China.
- Department of Clinical Laboratory, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang 324000, China.
ORCID-Profile: Nannan Zhang
Förderung
- China Postdoctoral Science Foundation
- Department of Education of Zhejiang Province
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Zhang, N., Zhou, J., Li, S., Cai, W., Ru, B., Hu, J., Liu, W., Liu, X., Tong, X., & Zheng, X. (2024). Advances in Nanoplatforms for Immunotherapy Applications Targeting the Tumor Microenvironment. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00846
Vancouver
Zhang N, Zhou J, Li S, Cai W, Ru B, Hu J, et al. Advances in Nanoplatforms for Immunotherapy Applications Targeting the Tumor Microenvironment. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.3c00846
BibTeX
@article{Zhang2024,
author = {Zhang, Nannan and Zhou, Junyu and Li, Shun and Cai, Wenjun and Ru, Bin and Hu, Jiaqi and Liu, Wenlong and Liu, Xuanxi and Tong, Xiangmin and Zheng, Xiaoyan},
title = {Advances in Nanoplatforms for Immunotherapy Applications Targeting the Tumor Microenvironment},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.3c00846}
}
EUVIMED